UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
nours per respons	e 0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person * DAUGHERTY BRUCE				2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306				3. Date of Earliest Transaction (Month/Day/Year) 06/21/2016						[X Officer (give title below) Other (specify below) See remarks					
(Street) NEW YORK, NY 10022			4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						Acqui	ired, Disposed of, or Beneficially Owned					
(Instr. 3) Dat			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)						Ownership of Form:	7. Nature of Indirect Beneficial Ownership
			(IVIOI	de			V	Amour	(A) or (D)	Price	(msu. 3 a	and 4)		or Indirect (I) (Instr. 4)	(Instr. 4)	
Common value	Stock, \$0.	001 par	06/21/2016			P	•		100,00	00 A	\$ 2	100,000			I	By IRA
Common value	Stock, \$0.	001 par										65,777			D	
Reminder: indirectly.	Report on a	separate line	for each class of	securities	s beneficially	owned	I	Pers	ons wh	n this for	m are	not req	uired to re	formation spond un	less	EC 1474 (9- 02)
			Table I		ative Securiti							ly Owned	I			
Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Y	Year) Execution Da	Date, if	ate, if Transaction Code (Year) (Instr. 8)		of		and Expiration Date (Month/Day/Year) US		Amo Undo Secu	ttle and bunt of erlying urities r. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Owners Form of Derivati Security Direct (or Indire	(Instr. 4)
					Code V	(A)	(D)	Date Exe		Expiration Date	Title	Amount or Number of Shares				
Repor	ting O	wners														

D (1 0 N (A))		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
DAUGHERTY BRUCE C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK, NY 10022			See remarks				

Signatures

/s/ Jessica Morris, Attorney-in-Fact	06/21/2016
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Chief Scientific Officer and Secretary

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.